background 9

The Antibody Discovery Specialists.

We are antibody discovery enthusiasts discovering biologics for our partners against the most challenging classes of reagent and therapeutic targets, royalty-free!


Contact Us On The Twist Bioscience Website

Twist announcement banner3



Twist announcement banner mobile
Contact Us On The Twist Bioscience Website

100+ Successful mAb Discovery Campaigns Targeting Cell Surface receptors.

Abveris provides industry-leading antibody discovery solutions for therapeutic and reagent antibody developers. We have built a strong reputation on our ability to deliver outstanding science. We have custom-built gene-to-antibody discovery solutions to support development efforts for:
  • Therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets
  • Cell therapies
  • Point-of-care diagnostics
  • Reagent & anti-idiotypic antibodies supporting clinical trials
  • Anywhere else antibodies are needed
  • Fee-for-service, royalty-free partnership model 


Expertise in Antibody Discovery

Industry-leading platform for challenging targets 
and royalty-free!


GPCR-1Cell surface-1High homology-2

Anti-id-1cross reactive-2Functional antibodies



End-to-End Antibody Discovery Technologies

Abveris is your premier antibody discovery specialist, offering end-to-end mAb discovery solutions to biotech and biopharma companies of all sizes. 


  • Proprietary hyperimmune mouse model DiversimAb
  • Humanized mice
  • Alpaca (for VHH via B cell workflow)
  • Specialty immunization
  • Antigen production 
  • Kinetic & epitope binning by Octet and Capterra
  • On-cell binding (iQue)
  • Custom activity assays
  • Small to mid-scale production to support different discovery workflows
  • Validation of binding and function
  • High-throughput in silicon humanization
  • Developability and sequence liability assessment to guide lead candidate selection

The Reviews Are In.

Pharma and biotech of various sizes and pipelines rely on Abveris for antibody discovery.

At Promega, we struggled to acquire a high-affinity, high-specificity antibody against one target of interest. After failing with two previous vendors, we enlisted the help of Abveris and their DiversimAb approach, and we soon had a multitude of high-quality clones to choose from. We eventually chose a clone that far exceeded our expectations for performance. We were continually impressed by their high-quality analytical data, excellent communication, and overall collaborative spirit.
Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
Jeff Goldberg, CEO
Immunitas Therapeutics

Contact the Antibody Discovery Specialists

Speak with Abveris scientists about how to tackle challenges in antibody discovery.

Contact Us On The Twist Bioscience Website

Abveris News